Free Trial
NASDAQ:ZBIO

Zenas BioPharma Q2 2025 Earnings Report

Zenas BioPharma logo
$16.57 +0.67 (+4.21%)
As of 01:26 PM Eastern

Zenas BioPharma EPS Results

Actual EPS
-$1.25
Consensus EPS
-$1.02
Beat/Miss
Missed by -$0.23
One Year Ago EPS
N/A

Zenas BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zenas BioPharma Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 12, 2025
Conference Call Time
7:00AM ET

Upcoming Earnings

Zenas BioPharma's Q3 2025 earnings is scheduled for Thursday, August 21, 2025

Zenas BioPharma Earnings Headlines

Zenas BioPharma Reports Q2 2025 Financial Results
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
See More Zenas BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email.

About Zenas BioPharma

Zenas BioPharma (NASDAQ:ZBIO) is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

View Zenas BioPharma Profile

More Earnings Resources from MarketBeat